OncoMatch/Clinical Trials/NCT06429449
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
Is NCT06429449 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Venetoclax and Azacitidine for leukemia.
Treatment: Venetoclax · Azacitidine · Mitoxantrone — This is an open label, phase 1 study for AML subjects with relapsed or refractory disease or subjects in morphologic remission with MRD+ after first line therapy with venetoclax+HMA. A preliminary dose-finding cohort will be followed by 3 expansion cohorts.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: venetoclax plus hypomethylating agent (venetoclax, azacitidine, decitabine) — first-line
treated with first-line venetoclax/HMA (azacitidine or decitabine)
Cannot have received: anthracycline
Any prior exposure to an anthracycline
Cannot have received: anthracenedione
Any prior exposure to an ... anthracenedione
Lab requirements
Kidney function
creatinine clearance ≥ 60 mL/min, CKD-EPI Creatinine Equation
Liver function
AST ≤ 3.0 × ULN; ALT ≤ 3.0 × ULN; bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome or leukemic organ involvement
Cardiac function
LVEF >50% by MUGA or ECHO within 1 month prior to study day 1
adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation; adequate heart function as measured by left ventricular ejection fraction (LVEF) >50%, assessed by multigated acquisition (MUGA) or echocardiogram (ECHO) within 1 month prior to study day 1; adequate liver function as demonstrated by: AST ≤ 3.0 × ULN; ALT ≤ 3.0 × ULN; bilirubin ≤ 1.5 × ULN, unless due to Gilbert's syndrome or leukemic organ involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Hospital · Aurora, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06429449 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anthracycline, anthracenedione disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages